OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
Subscribe To Our Newsletter & Stay Updated
